Final approval for Stavzor

FDA granted final approval for an NDA for Stavzor valproic acid from Banner (High Point, N.C.) and Noven (NASDAQ:NOVN) to treat manic episodes associated with bipolar disorder and to prevent migraines. In December, FDA granted tentative approval pending the July 29 expiration of exclusivity for Depakote divalproex from Abbott (NYSE:ABT). ...